By
Jim English
Vital Cell™ advanced herbal
formula has been shown to counter a host of common
discomforts associated with human aging. The following
summary, condensed from a clinical trial involving
150 patients, aged 55 to 89 years old, demonstrates
how Vital Cell confers a wide range of anti-aging benefits
to enhance energy levels, reduce plasma viscosity,
improve microcirculation and repair capillary damage.
By restoring microcirculation Vital
Cell promotes internal organ function while speeding
removal of cellular metabolic waste products, such
as lipofuscin, that have been implicated in age-related
degenerative health issues. Vital Cell has also been
shown to support immune performance by increasing resistance
to illness and improving overall health.
Researchers conducted detailed medical
examinations of each patient prior to the start of
the trial, and again at the end of the 30-day treatment
phase. After evaluating their data sets the researchers
discovered significant improvements in a wide range
of symptoms.
Angina,
Chest Tightness and Palpitations
With advanced age arteries tend to thicken as fatty
deposits accumulate on the inner lining of arterial
walls, especially in the coronary and cerebral arteries.
These deposits reduce arterial circumference and impair
blood vessel elasticity, resulting in a lack of blood
flow to heart tissues. Common symptoms usually include
chest distress, palpitations, insomnia, and pain due
to insufficient blood supply to the coronary arteries.
- Angina: Prior
to treatment 25 patients were diagnosed with angina
pectoris. After one month of treatment, 23 of the
25 patients (92%) were completely free of symptoms,
and the remaining 2 patients reported that their
symptoms were significantly reduced.
- Chest Tightness: Before
taking Vital Cell, 106 patients reported experiencing
chest pains. After receiving Vital Cell for one month,
only 2 of the 106 patients (1.3%) continued to experience
chest pains.
- Palpitations: Of
86 patients experiencing unpleasant sensations, including
irregular and/or forceful beating of the heart, 82
reported complete relief from symptoms one month
after treatment, and only 4 patients reported continued
symptoms.
Coughing,
Shortness of Breath
Human aging is associated with the partial or complete
wasting (atrophy) of the adrenal cortex and sex glands,
resulting in the deterioration of the mononuclear phagocyte
system (part of the immune system) and a decline in
antibody production for protection from infection.
Other factors, such as a narrowing or obstruction of
the pulmonary arteries, contribute to inflammation
of the bronchial walls, resulting in lung congestion,
edema, fibroplastic proliferation and narrowing of
the bronchial tubes. Symptoms include chronic coughing
and shortness of breath.
- Coughing: Before
receiving Vital Cell the patients were questioned
about their coughing patterns. Coughing fits lasting
5 minutes or longer, and occurring in both the morning
and evening, were considered diagnostically relevant.
Thirty-six patients reported that they experienced
bouts of coughing lasting longer than five minutes
in both morning and evening.
After taking Vital Cell for one month, 34 patients
reported improvement (94%), and only 2 cases reported
that coughing fits still lasted for more than 5 minutes.
- Shortness
of Breath: To determine shortness of breath
all 150 patients were required to climb one flight
of stairs, after which their breathing was monitored
and recorded. These records were compared to records
gathered at intake.
At the start of the study 42 patients experienced
shortness of breath during the stair test. At the
conclusion of the study only 7 patients still experienced
shortness of breath, while 35 patients (83%) were
able to complete the stair test without difficulty.
The difference was statistically significant (P<0.01).
Dizziness
Dizziness is one of the most common complaints of the
elderly. Originating in the central vestibule of
the brain stem, age-related dizziness is often related
to impaired blood flow caused by hardening of the
arteries.
Prior to the trial 69 patients reported
experiencing bouts of dizziness. After one month of
treatment 59 patients (85%) reported that their dizziness
had abated, while 10 patients (15%) still experienced
symptoms. The difference between the two groups of
patients is statistically significant (P<0.01).
Edema,
Puffiness of Lower Limbs
In the elderly, as plasma albumin levels decrease,
colloid osmotic pressure of the plasma is reduced as
well. Additionally, as aging blood vessels become increasingly
permeable, plasma levels of sex hormones decline, leading
to increased retention of water and sodium. Together
these changes contribute to increased accumulation
of fluid (edema) in the lower limbs.
Vital Cell has previously been shown
to increase plasma albumin and sex hormone levels,
leading researchers to theorize that the formula would
aid in reducing lower limb edema.
Prior to administration of Vital
Cell, 32 subjects were diagnosed with edema of the
lower limbs, including edema resulting from chronic
heart failure and chronic renal dysfunction. After
one month of treatment with Vital Cell 30 patients
(94%) were free of edema, and only 2 patients still
showed signs of swelling of the lower limbs.
Loss
of Appetite
The gradual decline of the hypothalamus-pituitary-adrenal
cortex is a hallmark of human aging. As the thyroid
glands deteriorate, secretion of digestive-system enzymes
and gastric juices is reduced, resulting in a loss
of appetite.
Before receiving Vital Cell, 56 patients
suffered from diminished appetite. At the conclusion
of the study 49 patients (87%) reported that their
appetite had returned, and only 7 patients continued
to show signs of a poor appetite after the treatment.
Blood
Pressure
In the elderly elevated systolic and diastolic blood
pressure levels result from the loss of elasticity
in the arterial walls. Other contributing factors include
a narrowing of the diameters of the blood vessels,
increased resistance to peripheral blood flow, and
elevated blood serum viscosity. Vital Cell has been
shown to exert a number of positive anti-aging effects
to aid in normalizing blood pressure levels.
Researchers measured blood pressure
levels of patients before and after treatment with
Vital Cell. Of the 150 volunteers, only those with
a systolic pressure greater than 160 and a diastolic
pressure greater than 90 were selected for further
evaluation, for a total of 62 subjects.
Before administration, 26 patients
had blood pressure measurements greater than 160/90.
The highest systolic pressure was 207, and the highest
diastolic pressure was 120. The average systolic pressure
was 149.78, and the average diastolic pressure was
89.4.
After receiving Vital Cell for 30
days blood pressure readings greater than 160/90 were
seen in only 3 subjects. The highest systolic pressure
of those who were treated was 150, while the average
dropped to 127.04. The highest diastolic pressure fell
to 100, while the average fell to 79.48. These improvements
were found to be statistically significant (P<0.01).
Improved
ECG
Of the 150 study patients admitted to the study, 48
were previously diagnosed with coronary heart disease.
Prior to receiving Vital Cell, ECG abnormalities were
detected in 35 patients, including ST-T changes, frequent
premature atrial beat, atrial fibrillation and frequent
premature ventricular beat.
Following treatment 30 patients (85%)
were shown to be free of the previously detected ECG
abnormalities, while 5 patients (15%) were found to
still have abnormal ECG's.
Blood
Flow
Researchers randomly gathered blood samples from 41
patients (20 males and 21 females) prior to treatment
and at the end of the study. The examiners conducted
the following tests on blood samples:
- Whole-blood specific viscosity
- Erythrocyte sedimentation rate
- Hematocrit
- Plasma specific viscosity
- Erythrocyte electrophoresis
While there were no detectible changes
in erythrocyte sedimentation rate or hematocrit after
treatment, test results revealed significant improvements
in whole-blood specific viscosity, plasma specific
viscosity and erythrocyte electrophoresis.
Microcirculation
51 patients were randomly chosen for observation of
nail-fold microcirculation prior to receiving Vital
Cell, and again after the 30-day treatment phase.
Microscopic measurements revealed
significant improvements in the speed of blood flowing
through the microcapillaries of the nail folds.
Immune
Function
To evaluate Vital Cell’s impact on immune function
the researchers selected 44 patients for blood tests.
Efficiency of the patients’ cellular immunity
was determined by measuring lymphocyte transformation
rate, and the immune function of red-blood-cells was
determined by erythrocyte rosette (E-rosette) formation.
- Lymphocyte Transformation
Rate: The average value before administration
of Vital Cell was 53.944. This value rose to
59.444 after one month of treatment. This was
a considerable increase showing statistical significance
(P<0.05).
- Test of Rosette
Formation: Average value prior to administration
of Vital Cell was 52.176. This value increased
greatly to 54.647 after treatment. The difference
was statistically significant. (P<0.05).
Metabolism
of Plasma Proteins
Albumin is an abundant blood plasma protein produced
by the liver and secreted into the blood. In addition
to preventing the leakage of fluids from the capillaries
into surrounding tissues, albumin aids in transporting
small molecules, such as calcium, unconjugated bilirubin,
free fatty acids, cortisol and thyroxine. Serum albumin
levels can serve as a useful marker of chronic liver
disease and nutritional status.
Researchers measured albumin levels
in 44 patients prior to administration with Vital Cell
and again at the end treatment.
- Plasma Albumin: The
average value of plasma albumin was 4.573 before
Vital Cell, and rose to 4.768 by the end of the
study. These numbers were statistically significant
(P<0.01).
- Plasma Globulin: Prior
to administration average plasma globulin was 2.734.
This number decreased to 2.564, indicating a statistically
significant improvement.
- Plasma Albumin
- Plasma Globulin Ratio: The ratio before
treatment was 1.702, and increased to 1.897 following
the treatment period. The difference indicated
a great statistical significance (P<0.01).
Summary
Vital Cell has been shown to have excellent therapeutic
actions on such elderly disorders as chest tightness,
insomnia, chest pains, coughing, shortness of breath,
heart palpitations, dizziness and lack of appetite.
Vital Cell has been shown to promote healthy blood
circulation while supporting expansion of coronary
arteries and arterioles of the brain and lungs, increasing
blood flow in coronary vessels, improving vessel
elasticity, enhancing T-cell immunity and promoting
the synthesis and metabolism of proteins. These findings
indicate that Vital Cell is a valuable antiaging
formula that can aid in reversing various disorders
affecting the elderly, such as insufficient blood
supply to the brain, coronary heart disease, chronic
bronchitis, and hypoproteinemia, without the risk
of adverse or toxic side-effects.
